Biogen CEO Chris Viehbacher at the Financial Times' US Pharma and Biotech Summit in May (Sarah Merians Photography for Endpoints News)
Hints of impatience grow with Biogen as it tries to find a bridge to growth
Biogen’s investors are growing restless.
Wednesday’s third-quarter earnings call checked most of the boxes for a successful report. The company raised its full-year guidance, and …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.